“PAIN IN NEURODEGENARATIVEDISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES”

A PROJECT SUBMITTED TO

NIRMA UNIVERSITY

In partial fulfillment of the requirements for the degree of

Bachelor of Pharmacy

BY

PANDYA PRIYA K (16BPH072)

Semester VIII

UNDER THE GUIDANCE OF

DR. SHITAL PANCHAL(Guide)

INSTITUTE OF PHARMACY

NIRMA UNIVERSITY

SARKHEJ-GANDHINAGAR HIGHWAY

AHMEDABAD-382481

GUJARAT, INDIA

MAY 2020

CERTIFICATE

This is to certify that **"PAIN IN NEURODEGENARATIVEDISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES"** *is the bonafide work carried out by* ***PANDYA PRIYA K*** *(16BPH072), B.Pharm semester VIII under our guidance and supervision in the Institute of Pharmacy, Nirma University, Ahmedabad during the academic year 2019-2020. This work is up to my satisfaction.*

Guide:

Dr. SHITAL PANCHAL
M. Pharm., Ph.D.,
Assistant professor,
Department of Pharmacology,
Institute of Pharmacy,
Nirma University.

DR.JIGNA SHAH
M. Pharm., Ph.D.,
Head, Department of pharmacology
Institute of Pharmacy,
Nirma University.

17/7/2020

PROF. MANJUNATH GHATE
M.Pharm., Ph.D.,
Director,
Institute of pharmacy,
Nirma University.

Date: 25/05/2020

CERTIFICATE OF SIMILARITY OF WORK

*This is to undertake that the B.Pharm. Project work entitled "***PAIN IN NEURODEGENARATIVEDISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES***" Submitted by PANDYA PRIYA K. (16BPH072), B.Pharm. Semester VIII is a bonafide review/research work carried out by me at the Institute of Pharmacy, Nirma University under the guidance of "DR. SHITAL PANCHAL". I am aware about the rules and regulations of Plagiarism policy of Nirma University, Ahmedabad. According to that, the review/research work carried out by me is not reported anywhere as per best of my Knowledge.*

Pandya Priya K (16BPH072),
Institute of Pharmacy
Nirma University
Sarkhej - Gandhinagar Highway
Ahmedabad-382481
Gujarat, India

Guide:

Dr. Shital Panchal
M. Pharm., Ph.D.,
Assiatant professor
Department of pharmacology
Institute of Pharmacy,
Nirma University

Date: 25/05/2020

DECLARATION

- *I, **PANDYA PRIYA K (16BPH072)**, student of VIIIth Semester of B.Pharm at Institute of Pharmacy, Nirma University, hereby declare that my project entitled "**PAIN IN NEURODEGENARATIVE DISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES**" is a result of culmination of my sincere efforts. I declare that the submitted project is done solely by me and to the best of my knowledge; no such work is done by any other person for the award of degree or diploma or for any other means. I also declare that all the information was collected from various primary sources (journals, patents, etc.) has been duly acknowledged in this project report.*



Pandya Priya K(16BPH072),
Institute of Pharmacy
Nirma University
Sarkhej - Gandhinagar Highway
Ahmedabad-382481
Gujarat, India

Date: 25/05/2020

ACKNOWLEDGEMENTS

I will like to take opportunity firstly to thank almighty for his constant shower of blessings in all my endeavors. I would also like to take the opportunity to express my heartily thanks to all those who are related to my thesis in some or the other way and have been a part to frame it.

Secondly I would like to thank my parents and guardian for their timely support and their absolute love for me.

In providing the fundamental picture of my thesis I would take this opportunity to express my heartily gratitude to my guide assistant professor, Department of pharmacology, Institute of Pharmacy, Nirma University to Dr. Shital panchal.

Her timely guidance and support provided shape to this project because of which I am truly grateful.

Lastly I would like to thank Dr Manjunath Ghate for providing platform to showcase my talent regarding this thesis.

"PAIN IN NEURODEGENARATIVE DISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES"

INDEX

INDEX FOR FIGURES

INDEX FOR TABLES

"PAIN IN NEURODEGENARATIVE DISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES"

1.INTRODUCTION

When a nerve fiber is injured , various changes occur in the nerve fiber and nerve cell body. All these changes are together called the degenerative changes.

Degeneration refers to detoriation or impairment or pathological changes of an injured tissue. when a peripheral nerve fiber is injured the degenerative changes occur in the neuron and the nerve fiber of same neuron and the adjoining neuron.

Neurodegenerative disorders have traditionally been classified according to clinical criteria, e.g. as dementia syndromes (the best known is Alzheimer's disease) or as movement disorders (e.g. Parkinson's disease) .

Alzheimer's infection has clusters of two primary proteins: beta-amyloid and tau. Clusters of beta-amyloid are called plaques, and tau bunches are called tangles. In Alzheimer the patient has dementia ,partial or total memory loss. Individuals who experience the ill effects of subjective disability, may have an expanded affectability to pain. The specialists found that experiencing pain is higher in those with mild to moderate Alzheimer's, though pain sensitivity is more unclearly in those advanced types of the illness.

Parkinson's disease has Lewy bodies in key zones of the cerebrum that control development; Lewy bodies are made out of the protein alpha-synuclein. In parkinson's patient gradually suffer from tremor in finger, hand&foot with limb stiffness & slow movement (bradykinesia) and also stooped posture is seen

Both the diseases are irreversible and uncureable so that it can lead to death. scientist are searching a way to come out of this situation and the reasearch is continuing[1][2]

"PAIN IN NEURODEGENARATIVE DISEASE: PARKINSON'S AND ALZHEIMER'S DISEASES"

Parkinson's diseases (PD):

Patient who is suffering from parkinson's disease often experience pain. nowadays pain is commonly accepted to represent one of the PD non motor symptoms having a remarkable impact on the patients quality of life.

While pain was considered initially as an epiphenomenon of the motor impairment

characteristic of the disease, the attention toward this symptom

has increased in the last many years.

Two primary components driven clinical and research effort to understand the pain mechanism in PD.(1) The higher prevalence of pain in PD patient compared to that in the healthy elderly subjects and patients compared to that in the healthy elderly subjects and (2) The inclusion of nondystonic body parts, which implies that pain is potentially connected to the inherent pathophysiological mechanism of the disease.[1][2][3]

Pain frequency and clinical Features:

Five types of pain can be observed:

(1) Musculoskeletal,

(2) Redicular-neuropathic,

(3) Dystonic,

(4) Central neuropathic,

(5) Akathisia pain.

The pain is classified between nociceptive and neuropathic pain. Normally patient feel the nociceptive pain which can be musculoskeletal.

musculoskeletal pain derives from abnormal posture of dystonic part of the body ,rigidity and kinesis.[4][5]

1)Musculoskeletal :

Those conditions affect their limbs, nerves, tendons, also connective tissue specifically. The first and most widely recognized cause of neuropathic pain was skull, tendon, link as well as dislocated patella. Drops, related injuries, or collisions were only a few of events which can cause pain. There are over 100 musculoskeletal disorders which lead to the diseases of parkinson. [4]

2) Redicular-neuropathic:

This is now the sensation that emits via the bones through back muscles from either the neck or down from the top. This will be situated by both the touch of a tendon throughout the body. That wide variety among signs were feeling like sharp pains hurting including fatigue , tingling. It may happens via trauma with frustration.[4]

3) Dystonia:

Neuropathy is indeed a condition of neurological development wherein constant either repetitive muscles resuscitation result in twisting as well as repetitive movements, even odd static positions. After quite a spasm, innovations can gain traction.[4]

4) Central neuropathic,

Core discomfort condition seems to be a chronic pelvic pain illness caused through cns injury. This might happen during trauma, concussion, nor damage to the spine. It could

be found alongside disorders including muscular dystrophy and Parkinson's, moreover.[4]

5) Akathisia pain.

we just don't really grasp Akathisia properly. It is a quite complex situation were suffering appears like such a mysterious operation of disturbances. Its feel regular, repeated motions such as walking, swinging back and forth while wobbling. so that it is akathisia.[4]

Clinical and Instrumental Assessment:

Although discomfort becomes prevalent too in PD, and the most studies conducted who used new measures not quite special and unique to this little neurological disorder. also a very recent public randomized controlled study recorded only the last trauma-specific PD measure. [12][13]

Clinical Characteristics of PD

PD is a chronic disorder with a median age at the beginning of 55, and the incidence increases exponentially with age, from 20/100,000 in total to 120/100,000 at 70 years. There is no clear genetic correlation in around 95 per cent of PD cases (referred to as "sporadic" pd).[8] But the disorder is inherited in the remaining cases. Over time, symptoms escalate, and the mortality rate for patients with PD was three times that of typical age-matched subjects prior to the introduction of levodopa. Although levodopa has significantly improved living standards for PD patients, Population-based studies indicate that these patients tend to have decreased survival relative to the general Hely et al. population in 1989, Morgante et al. in 2000, Levy et al. in 2002.[9] Moreover, after 5–10 years of illness, most PD patients experience significant motor dysfunction, even though they are expertly treated with available symptomatic medication. Clinically, any disease involving a striatal DA deficiency or direct striatal damage can result in

"parkinsonism," a syndrome characterized by resting tremor, rigidity, slowness or absence of voluntary movement, postural instability and freezing (Table 1). PD is the most common cause of parkinsonism, comprising 80% of cases.[10]

Table . Parkinsonian Syndromes

Primary Parkinsonicism	
Parkinsons disease (sporadic, familial)	
Secondary Parkinsonicism	
Drug-induceed: dopamine antagonists and depletors	
Hemiatrophy-hemiparkinsonism	
Hydrocephalus: normal pressure hydrocephalus	
Hypoxia	
Infectious: postencephalitic	
Metabolic: parathyroid dysfunction	
Toxin: Mn, CO, MPTP, cyanide	
Trauma	
Tumor	
Vascular: multiinfarct state	

Primary Parkinsonicism	
Parkinson-plus Syndromes	
Cortical-basal ganglionic degeneration	
Dementia syndromes: Alzheimer disease, diffuse Lewy body disease, frontotemporal dementia	
Lytico-Bodig (Guamanian Parkinsonism-dementia-ALS)	
Multiple system atrophy syndromes: striatonigral degeneration, Shy-Drager syndrome, sporadic olivopontocerebellar degeneration (OPCA), motor neuron disease-parkinsonism	
Progressive pallidal atrophy	
Progressive supranuclear palsy	
Familial Neurodegenerative Diseases	
Hallervorden-Spatz disease	
Huntington disease	
Lubag (X-linked dystonia-parkinsonism)	
Mitochondrial cytopathies with striatal necrosis	
Neuroacanthocytosis	

Primary Parkinsonicism	
Wilson disease	

PD spasm happens with vast majority however reduces eith compulsory exercise, so it typically doesn't affect daily living.[11][12][13] Stiffness relates through increasing resistance (softness) towards active motion of such an individual's joints Bradykinsia (smooth action), hypokineasia (significant decreasea action frequency), even akineasia (lack off usual unwanted muscle spasms, along with swinging the limb off wandering) occur ass either varieaty off causes comprising removal off ordinary tone off voice (hypomimiia), reduced tone off language (hypophoniaa), Slavering (disaster can suck through worrying about doing it), reducing scale (micrograaphy) including speed and reading, as well as increased action frequency when moving. Bradykinaesia could have a significant impact on the future of lives, when everyday activities including behaving or snacking take more time. PD clients typically build slumped stance and may weaken normal neuromuscular motor skills, resulting in drops or sometimes disability confining. Cold is indeed a comon sign during parkinsonicm, its inability will activate ae voluntary activity including moving (i.e., individuals stay "trapped" to both the field when moving). many were often various emotion / neurological diseases; individuals can become inactive either depressed, avoiding strategy; they could remain silently till thy r prompted for participate into action. Answers to questions were delayed, yet executive processes ('bradyphrrenia') were slowing down. Anxiety becomes natural, however PD was probably more comon in alzheimer, especially with the patients with age. [14][15]

Neurochemical and Neuropathological Features of PD

PD's medical featuraes were in the unavailability off nigrostriatal dopamineargic neurones, and the production off extracellular intraaneuronal amino acid additions named "Lewy Bodyies" (LBs) Dopamine transporters nerve celll organs were in the SNpc but are still exclusively projecting putamen. Complete destruction of such nerves, normally producing prominent amounts to neuromealanin (Marsdean, 1983), causes that famous extreme neuropathologicl observation off SNpc hyperkeratosis. SNpc cells failure behavior appears to represent the degree of transmission of DA Transformer (DAT) mRN.[15][16] That's associated with both the finding that only in the dorsolatral putamean (Bernheimer at 1973), main translation place because of these neuronal, the worst noticeable impairment of DA happens. At beginning of the effects, putameanal DA is decreased by ~80%, and ~60% dopaminergic neurons from SNpc have now been killed. Throughout PD the mesolimbec neurotransmitter nerves, whom neuronal structures originate in the dorsal teggmental area (VTA) lateral to the SNpc, are significantly reduced influenced . Accordingly, their cauudate , the main dissemination place for all these nerves, shows significantly reduced DA failure.[17]



Neuropathology of **PD:**

(A) Schemetic diagram of the standard dopamine system (inn burnt orange). This comprised of nicotinic acetylcholine receptors eith tissue corpses throughout the hammers compactta ventral striatum (SNpc see lightning bolts). These nerves transfer to both the cerebellum (stiff penalty try rows) and to synaepse in the hypothalamus (i.e. putamean and caudatae nucles).The image reveals usual SNpc pigmentatin produced by neuromelanene within the dopaminergicc neurons.[18][19] (B) Schemetic overview of

the deformed dopamine pathway complex (in red). In Parkinson'sdiseases the Dopamine Pathwey perverts. There was a noticeable failure of dopaminergec neuroens projected to putamean (dark red strong row) as well as a more subtle reduction to the reticular formation from those who estimate. That image indicates decalcification off it's SNpc (i.e. reduction and gloomy-brown neuromelanine colour; swords) leading with significant neuronal neurotransmitter deficiency. (CSNpc neurotransmitter nerve Intraneuroneal immunohistochamical tagging, including Lawy heads. Immunostainiing via n a-synuclein vaccine reveals a Lawy organ (dark skinned bow) covered by mildly imunoactive lateral area with just a strongly imunoactive cantral region.(left image) Contrarily, imunostaining at an enzyme in the Lawy bodyy with microtubule yields further convective immunostainability.(right image)[17][18][19].

Neuropatholoagical observations in PD-associated neurodegenerative diseases suggest possible explanations for the pathophysiology of the condition. Second, there is a distinctive topoology of nicotinic acetylcholine receptors connected by PD, [20]than the pattern shown during normal aging. in PD, neuron death is clustered in the ventroleateral and dorsal sections of the SNpc, while in ageing the dorosomedial portion of SNpc is affected (Fearnaley and Leees). Thus, while aging is a causative factor for PD, it is probably that structures that activate era-related neural cholinergic loss were distinct from others in PD. Sec, the amount of neural failure in the cortex appears to be more extreme than even the level of SNpc neurotransmitter neural damage , suggesting that the real target of the neurological mechanism is hypothalamic neurotransmitter nerves nodes, and that neural failure in PD-resulting from a phase of "dieing home". Empirical data for the concept of died back comprises observations that the demise of neuronal targets in chimpanzees controlled with MPTPp precedes that of SNpc membrane corpses (Herkennham et al.), and the safety of neuronal nerves in rodents diagnosed with MPTPp preavents the failure of SNpc neurotransmitter neuronesThird, the syneptic DAa clearance proceess in the hypothalamus

appears to be more DAT-reliant than the hippocampus, in which some monoaminеargic providers and the neurotransmitter amino acid cateachol-O-methyltransferase play a significant role in halting DaA Government checks actions. Nervous system is a domain controller for the measurement of Neuronal neuronal cells, so this difference might be important in creating the notice things of VTA nerve cells to PD-related deterioration[21][22] Variations The substantiaanigra neuroapil, which involves of striaatum and glaobus palliadus cortex projects, significantly labs for calbindinaD28 K, as well as most neurotransmitter neuron groups remain within this calbindin-rich neuropila (Damier). After all, the susceptible PD nerve cells show up to be present in calbindina-poor areaa of substantiaanigra. Dopaminergiac collagen fibers were also formed in the synaptic subculture all over SNpc. When it is generally thought that PD neuropaethology is perceived by neurotransmitter nerve cell failure on its own, neurodegenearation expands well beyond dopamineargic neuron(reviewed by Hornykaiewicz and Mok,). Cellular senescence and LBB are developed in noraedrenergic (alleles coerualeus), serotonin (raaphe) and receptors (Meyneart's neuron baasalis, the dorsal horn neuron of the therefore it) structures including in frontal lobe (— particularly parietal lobes and entoarhinic coarticles), olfaction tubes and adaptive immune processes. Deterioration of neuronal functions and dopaminergic cerebral influences correlate to the higher prevalence of alzheimer that occurs PD, particularly in older clients[23]. Even so, the allows opportunities of damages on serotonin and cholinergic structures are not established as reliably as are damages to the dopamiane receptor mechanism. Therefore, though it is generally accepted that intervention of these neurobiological processes exists in more severe or delayed-stage illness, it wasn't well understood the causal association of injury to various neurobiological processes. Some clients, for instance, encounter stress weeks or months before the start of PD movement effects, which can be due to early

intervention of nondopameinergic mechanisms. Through nature, evaluation of PD is performed on diagnosis based but positive result includes identification both of LB and SNpc noradrenergic nerve malfunction. Though, LBs were not specific to PD but are also prevalent in AD, in a condition known "LB condition depression," and as an unintended abnormal discovery in senior citizens at a greater frequency then PD.[24] That position of LB in neurodegeneration is contentious, as are the reasons for its high rate in AD and the connection of the indirect LB with the frequency of PD. LBs are abstracts of circular intracellular receptors composed of different genes , available in all afflicted brain areas, except a-synuclein, parkin, ubiquitien, Forno, Spillantini . and LBs seem to be more then 15 μm, and get a layered crystalline that comprises a thick hyaeline center accompanied by a transparent glow. A dense granuloveasicular core covered by a rim of murphy and Tennysonn , Pappaolla radiaeting 8–10 nm fibrillar, is seen in spectroscopy.

Pathophysiological pathway of pain in PD:

That source causing discomfort during PD continues interpreted as ineffectually. So it appears as just a neuropathy for times while wearing off both the dopaminergic (DA) effects. Its neurophysiological materials behind the whole concept are frequently relevant whereby neurotransmitter, of instance noradrenaline or 5-hydroxytryptamine (5-HT) in a program eith varying monoamine neurotransmitters, binds via inhibitory as well as excitatory routes. Deformity in slipping networks influences the transmission of central discomfort. Sufferers with PD are most often presented with medically engaged neuropathy as well as other severe pain experiences. This may have triggered work into mechanisms except for those mandatory of implacable existence, spasm, or any other disorder motion signs, with its most likely culprit being abnormal nociception in PD clients. That basal ganglia (BG) stores limbic evidence in unique ways, and it has been compensated of in PD clinicians through increased mental distress affectability of

lowered magnetic / warmth intensity levels. Such abnormal preparation also includes PD-related muddles, e.g. cortical inflammation, who demonstrates a discomfort close to PD. Various integrated systems including connections define a functional biological planes of basal ganglia. Basal ganglia step in in the interaction of activity responses with signals as just a guiding center for reticular formation fibres. That influx of the cortical & subcortical brain regions contributes thalamus, amygdala and basal ganglia to the network. The below cortical areas often take up considerable work whilst also as well as pain management. Such areas have included the prefrontal as well as cerebellum structures, that hippocampus and thus the cortex. Electromagnetic incitation of substeantia nigra, one off the nueclei throughout the BGg, manages increasing discomfort withi in thhe spinal cord's dorsaal horrn, which has been likely interfered with through a DA falling intracellular cascade beginning in the midbrain.Its neurophysiological hypothesis for neurological irritations during PD, its assumed "painmatrix" assembled in the BG using information from multiple loci.[24][25].



Figure.2

Those twin main DA paths were viewed allover. The course of nigrostriatal DA extends from of the substeantia nigra too doersal striatael complexes in the corpous striattum. The program has a research building up in combining through managing that sensorimotor. Subcortical structures of amygdala, thalamus, and nucleus accumbens join nerves with such an source throughout the dorsal tegmental zone Particular cortical regions, other than motor cortex as well as prefrontal cortex, are further derived from both the parietal tegmental region via separate simulations. Consequentially, there is indeed a large overlap between certain DA system and also the regiones of the brain described implicated inn pain control, and mortor and somatic symptoms that results from interference in DA amounts in all of these places.[26][27] Most work suggests that some other places along with brain-stem nuclei as well as diencephalic constructs are often impacted, whereas additional-encephalic constructs, the spine and autonomic bacterial plexus appear to be implicated as well. Furthermore, because DA medicines could be

helpful fore many other NmMS, includiing PD pain, evidence shows thet all thase signs are connected eith DAa surgical excision in regions not always generally associated to ms in the cerebellum.[28]

Dopamine signaling pathway



That failure of nicotinic acetylcholine receptors in the substaenianigra region of the dorsal cerebellum is described by bradykineasia, sitting spasms, and steadiness. In reasonable level, releasing the motor neurons in the synapse nerve results in activation of the sensory neurons by dopamiane receaptors of the type D1 and D2. D1 neurons frequency cyclic nucleotide installation through G-proteins, sparking the emergence of caAMP, and initiation of PKaA. To block this signaaling, the D2-type receaptors inhibit adenylatae cyclase. Parkinson'sdisease may arise into both biological (family) variation and ambient and (irregular) exposures to known carcinogen. [28][29][30]

Lysosomal storage loss-of - function organisms in hess, DJ-1, as well as PINK1 inflammatory cytokines and absorption of superoxide anion species (ROS), while dominantly inherited violence abnormalities in asynuclein and LRRK2 significantly impact Things for nutritional degeneration, leading in tau protein and the accumulation of Lawy parts of the body. Their untimely deterioration in nicotinic acetylcholine receptors could be accountable for the cellular senescence and amino acids accumulation.[29][30]

A further specific trait of the mutants a-synuclein, Parkinn, DJ-1, PINK11, and LRrRK2 is the deficiency of dopaminaergic and dopaminae levels neurotransmitter, which could be an advanced bacterial trigger preceding neuronal cell destruction. Exposed to the climate and pathogen may also major contributor mitochondreial damage and activation of Superoxide, leading to a number of cell survival involving cell death and destruction of protein synthesis frameworks. This diseases also involves a scarification that results from inhibition of macrophages causing the production of cytokianes and charges. The whole formation of macrophage activates apoptotic cell death via JNK path that leads or stopping the sensing paths via REDDd1 to the Akte.[30]

Physiological pathways of pain relief

Thoughts which have been originally created by Melzack as well as Wall were introduced in the early 1960s. We proposed three ventral tegmental area validation qualities signed for distress: your continued interaction previous stimulation, deficit-evolved behavior, as well as the compared behavior consistency of huge vs tiny

fibres. somewhere in the spinal cord, pain signals experience "nerve gates" that open and close dependent on such a range of factors (including possibly brain guidance). Whenever the valves are opened, stress signals "move" easier, however discomfort could be serious. Whenever the valves are closed, pain impulses were banned from entering the brain, but may not become felt. Whereas the complexities of this method were still poorly known, it might help to explain the effectiveness of specific symptoms. The existence of afferents with small-threashold machanoreceptive C-tactiale (CT) was initialy describad by Valbo et al. These affferents generate separate network that becomes physiologically or functionally unique, and that affects humanity[31] That presence of all these structures suits limbic processes quite strongly then cognitive but motor activities. Although fast, accurate, even informative Aβ contact acutely expresses that outside universe thru somatic activities in an exteroceptive way, CT trigger integrates several features of interceptive methods. This slow, effective temperament would definitely perform a vital role in promoting physiological well-beaing.[31]

Measurement of pain:

Both stresses, and also the biomarkaers.

That stresss and pain were also closealy connected. Increasing influences another, perpetuating the cycle which is setting the foundation for severe pain and psychological distress. Managing tension will also form an essential part of trauma treatment. here the Merrriam-Webster online encyclopadia describes the term stress and anxiety as a "real physical, chemical or emotionally charged force that causes entire body and or mind a bit distress, and can be a factor in deadly disease correlation and causation." perhaps the overall outcome of stress and anxiety can become defined in terms of physical or mental discomfort problems arising mostly from stimuli that seem to change an existing equilibrium point. Stress is also a human response to difficult situations, and even harmful ones. The profession of scientific value was the search for immunological enzymes which reflect representations of body pain. That reflex to "fight or flight" happens whenever a individual recognizes a danger as well as the organism imparts

power to battle or ran away for "live each day."This behavior is marked via epinephrine released from both the adrenal glands, who triggers artery constriction with fetal heart rise. Testing for hormone concentrations throughout secretion has proven the strong and secure biomarker of specific distressBy studying that position off that same hypothalamicc – pittuitary – adrenel axis and cortisol secretion as the surroggate predictor for pressure and relative discomfort in persons eith PD,,stress / pain management results could be detected and objectivized. Some biomarkers were the vasopressor, norepinephrine, and oxytocin quantities. Many tests to evaluate stress management include blood pressure, and cardiac and breathing rates.[31][32]

Examples of pain scales

A Visueal Analogue Scalae (VAS) evaluates a continum off a selected phenomenon current. An eg, any suffering a person feels experienced varies of no pain to intensive pain severity around a spectrum. This continum of intense suffering feels infinite for both the clientStress may not occur as just an usual spectrum of variations betwen both the qualities, as separate, moderate, and severe. Words descriptors (WDSs) are only used at either halves of that same line, normally 100 mm long. That measurement is heavily subjactive and is often done in an entity, but not between entity users at the same time. Many critics argue that even a VAS will at best produce data of an integer kind. It was vital to know when systematically analyzing the Vas results. Grade organization of results could be the best way to manage patient data on the 100 mg axis, instead of just the precise ratings. [32][33]Track record on suffering. The Description Control Server was initially created for people with cencar via palliative care. It tests pain management, reliability of pain, and clinical understanding of results of injury in the sort of pain strength (auditory aspect) and diagnosis of distress (aggressive multiverse). There really is, to date, not clear verified scale commonly used for the field of PD-related stress (PD pain). Hence explaining the sense of a report in the this area is significant. Very importantly, It developed the queen's PD level of pain. This scale is simple to administer, allowing the interviewer to ask queries and complaints for each person, as well as

determining the severity of PD intensity. It will take the social worker and the customer ~10–15 seconds to complete. Seven-domain data provide details on different forms of PD pain generally defined as both somatic and spasticity mechanisms. In addition, the system measures pain ranging from time dependent stress associated with failure of antiparkinosonic medication influences, i.e. bringing off-site pain to central, oroefacial, and nerve entrapment pain.

Clinical diagnosis of PD-related pain classification

Traditionally, distress in PD is composed of five areas: specific ion, grolier / neurogenic, social role-related, akatahic, And it's important. Neuromuscular, and clonic types are the four common pain disorders. Core PD discomfort was far less frequent but recognizable; it can be intermittent or persistent in duration, and is frequently described by clients as intermittent pain, fire, or heavy bleeding. This is because of no cyst in the brainstem. Various sections of the body may well be influenced, and are often identified with independent effects. There are no specific pain reports from back, abdomen, or perhaps even mucosal membranes.[32][33] Nevertheless, the concept of essential distress is not reliable, and the word for core neuropathy which also has a broader meaning is not easily misunderstood. Specific structures are often involved in syndromes of PD pain, but that's not comparable to fulfilling the core need for neuropathy.



Clinical decisions

Although PD cases exhibit the indicators of distress the physician can again determine when the distress is attributed fromPD. Figure can be used to support in this evaluation. The connections among stress stimuli and switchable neurological dysfunction are critical in assessing the cause of discomfort and may help pharmacological intervention by substituting serotonin. Also critical is the evaluation of the client's condition, since sleep problems need medication strategies. Furthermore, the correlation regarding stress, neuropathic discomfort and PD remains controversial.[332][33] Bipolar disorder may well be related to PD distress or conversely or the dual symptoms may literally exist side by side. Brain chemical data suggests that symptoms of disease, pain and nausea in PD clinicians may have popular behavioral coatings.

Location-specific pain in PD

Soreness in the belly. Stomach pain or others types of stomach issues, for example dyspnea, are common in PD. Therefore, it is essential to distinguish menstrual cramping connected eith DA loaded variants from certain forms of stomach pain, such as

pancreatitis and bronchial heartburn. Assistance regarding time associations with absorption of DA and then on-off signs could be given. Suffering back problems. Another study recorded the frequency of spine treatment in children with PD increasing to 23% which is substantially higher in the rest of the population than all of this[32][33][34]. To the arm. Discomfort. In 11 percent, 43 percent, or 80 percent of PD incidents, limb inflammatory has been observed in different studies but is absolutely inappropriate during an orthodontists disorder. In contrast, the psychologist should be recommended that it might be a foreboding sign of aggression associated with Tampa.

Pressure feelings fluctuate to pd

Variations of just the NMS variations were homogeneous but complicated. Psychological NMS claims may rise or fall often commonly and far more intensely then nonpsychic signs.

Treatment

Diagnosis is emblematic for all Parkinsonn's cases, based on strengthening movement possible signs (e.g., facial twitch, stiffness, bradykinaesia) nd anti-motor (e.g., constipetion, vision, behavior, nap). Some pharmaceutical drugs affect a disorder. Usually, the original movement effects are stimulated by therapies dependent on neurotrans. Nonnmotor signs involve level of e therapies (e.g., specific clinical signs of dopamiane antagonists, cholinergic cognitive blockers); pharmacotherapy supplements the recovery and relaxation exercises. People with mental illness, such as cardiac issues and loss of feeling when an injection of prescription wore apart ("off key moments"), medicine-resistant spasm, or dyskinaesias, profit frm advancaed therapies including levoadopa-carbidopa intravenous drivetrain therapeutic or neural stimulus.[33][34] Medical treatment is indeed a part of managing Parkinnson's diseases.

Alzheimer's disease:

Alzheimer's diseases (AD), also actually referred to as dementia, is a chronic neurodegenearative process that usually tends to develop gradually throughout time. This

is the origin of 60-70 percant of neurodegenerative diseases. Its most successful new sign is discomfort in informing about today's developmentsSide effects might include languaege issues, dizziness (along with readily being gone), irritability, reduction of determination, desire for self-care administrators, and hyperactivity as the condition worsens. As an employee's situation declines they periodically disconnect to society. Bodily fluids slowly get affected, ultimately causing death Although report highlights will differ, their median survival rate after diagnoses is four to eight years. It wasn't well understood what causes dementia. Almost 70 % of a hazard is thought to be transmitted out of a baby's parents, although usually involving specific genes[36][37]. Many medical conditions include fatigue background, anxiety, and high blood pressure; The illness circuit associates inscriptions and neuromuscular junctions in within cerebral cortex. A possible prediction is dependent on the experience of the disease, and neurological review with nuclear medicine and diagnostic tests to eliminate contributing causes. These clinical symptoms are often mistaken for normal ageing. The conclusive evaluation may require muscle cell examination&Mentally and physically activities might decrease the risk of AD and prevent fatness; although, there's no evidence supporting these advice.[36]37] There are almost no pharmaceutical products or nutrients included to decrease the severity. Few therapy could prevent even restore it's own growth, although others may potentially relieve the signs. Persons impaired are wholly reliant on anyone to receive assistance, often imposing a pressure on the patient. Those burdens can also include components of either a public, physiological, mental, including financial existence. In spite of general life habits, workout strategies can indeed be effective, and therefore can eventually boost performance. Behavior issues or anxiety associated of alzheimer were frequently diagnosed with antidepressants but this is not commonly advised because there is little advantage as well as an increased chance of premature death. In 2015 there's been roughly 29.8 million individuals with AD globally. This happens more often in adults above an era around 65, however parkinson's disease initial-onset is 4–5 per cent of the sample. It influences approximately 6 per half of the people aged 65.[38] In 2015 Alzheimer's culminated in approximately 1.9 million

casualties. In 1906 it was first described by germen scientist and neuropsychologist Aloeis Alzhaeimer, and later namad affter it. AD was one of the most costly infections in developing world, economically.

Pain Frequency and Clinical Features in AD

Persons through alzheimer are still suffering through multiple pain-related health conditions because of an elderly era. Even then, the overall incidence of distress in alzheimers is unclear leading to a shortage of self-report as previously stated in this number of students. Experiments including objective pain assessment techniques indicate that only about 50 per cent of people with dementea in care facilities experience discomfort. This one is consistent with just the rates of susceptibility reported for hospital clients, independent of their cognaitive abilities.[36][38] But the occurrence of discomfort in elderly people has to do with the intensity of the disorder. In fact, people who live in care homes report approximately 45 million and 83 million cent of dyspnea discomfortSeveral of those clients had registered severe conditions (3–6 weeks at most) (approximately 94 million). That sources of pain symptoms in alzheimer care homes involve, or are not specific towards, gynecologic conditions, cardiovascular syndromes, presssure sores and skine infections, both being reported in 95 per cent of cases and described as among the most comon ailments in this field population. Many research also identified discomfort incidence between individuals living at residence with alzheimer. Those occurrence figures were described throughout the chart Whatever seems clear was that the results varies through studies, dependent on where they are dependent on the body-report or even the information of the guardians[39]. Many reports also identified discomfort incidence rates between clinicians live at home with alzheimer. All thease frequency levels were found Whatever sems evident was that the levels vary through studies, focusing on how their are focused on both the body-report or even the results of the clinicians.

Clinical and Instrumental Assessment

Despite its significant prevalence of discomfort in older persons, effective and safe control requires detailed examination of discomfort by professionals including medical professionals or relatives. Examination of discomfort in patients is always a concern because of the complex and complicated complexity of the medical perception. The higher the mental handicap, and therefore the higher the leck of emotional-report, the larger the mission. Nurses should depend onn self-reporting to thease situations, than on therapeutic pain treatments. Especially face features generally give the clients a simple indication of discomfort. Demeantia sufferers show a certain kinds of expressions as upcoming examination people in regards to pain. So, that emotional adjective's strange quirk to discomfort was n't diminished.[39]40][41] The whole side effect indicates which face expresssions of discomfort are capable of acting as just an appropriate benchmark of discomfort in clients with alzheimers. Certain approaches to measuring discomfort covertly were also particular measurements of evaluation of acts (figure, besides instance, mein fuhrer . but also Zwaekhalen et al for depth instructions). Though, the research process for those measurements has already started. While the initial results are optimistic, further work is required to define which artifacts separate discomfort behaviour and activities in clients with alzheimer from other types of unmeet neeeds. Scientists all over north america began researching behind a Euroapean action plan (TD1005) Whether the psychosocial aspects could also expressly reveal postoperative discomfort with varying stages of mental impairment. Its loop was under way and it willl hopefully become done over the naxt 1-2 decades.

Clinical Characteristics of AD

This clinecal trials phase in dementia is innocuous there are, maybe by necessity, few reliable but rather specific symptoms and indicators which will provide over a very early

detection before irreversible damage occurs. For a condition of psychiatric alzheimer mental problem could be too severe to impact the tasks Adult neurogenesis problems were usually normal well into the initial steage of alzheimers; suicidal signs were not intermittent, however the individual normally tends to live isolated.[42][43] Descriptive memoery loss were typically normal in the early phase of the disease; suicidal effects weren't rare however the individual prefers to stay alon fact Overall death rate in people with just a formal diagnosise of acute has significantly reduced but then to continue it was optimism also that period of overall quality of life-being but not distress can be increased with existing diagnosable care methods.

Possible Pathophysiological Mechanisms

Just a couple longitudinal trials have tried to explore whether alzheimear's impacts the transmission of neuronal material, with other work focused on individuals with Alzheimear (see Defrin). Disturbingly, some laboratory findings tend to show that somehow the sensitivity and sensation of discomfort were not diminished in people with moderate to extreme forms of demaentia.[44][45] That sense of discomfort can be enhanced along the contrary. Demeantia sufferers were confirmed to pay attention to noxieous stiimuli too includes replies and discomfort drawdown dexterity comparison to older adults physicians. Responsive mass spectroscopy microscopy (fMRI) researches tend to shown brain activiety through individuals with chronic signs of Alzheimear's diseases is retained but even improved, trying to verify findings specific fecial nd reactionary gestures. Yet another research showed no effect in peaek frequency respectively controal subjects which use invokes simple boolean (ERPs), but one research paper did not trigger pain-evoaked possibility in the severe alzheimer's subcategory[46][47] Each systemic head trauma which develops while impairment which mostly often influences depressive mechanisms of stress regulation in modaerate to severe steages of the disease, due to lower behavioral inhibition of the fear response and intensified pein medication. In the future date of alzheimers, the downward nerve endings can be more significantly impeaired, leading to reduced analgesia. However, it's just

conjecture, because thare isa absence of significant phase of alzheimer trials on individuals.

The neurology of pain in AD

Pain Processing in People With AD

Neuropathologiceal chemical changaes that arise in AD could intravenously or neurologically influence the recollection, interpretation, and documentation of distress. Results of the study described throughout the new survey of individuals with AD 's ability for vocal or behavioral pain communication indicate combined affected individuals documented decreased, enhanced, or normal visual, affectiive , and beheavioral reactions to pain signals. [48]Major contributors to inconsistencies of experiments of dynamical or even pathophysiological discomfort in demeantia sufferers usually involve: reserch strategy, relation to the literature of the patients and severe and chroniec conditiions. Despite such conflicting results, few reports has reported a loss for discomfort statement in individuals for AD.

Pain Assessment in People With AD

Although the contextual self-reaport of discomfort in chronic stroke folks is thought to be important for pein management, self-reporting of none – verbal individuals with developed AD isn't really viable. [49][50]Assessing braine function in areas involved of drug therapy mostly during postage of neurotoxicity sensory input in the research facility that represent as a prognostic measure or determinant of preserved pain transmission in individuals who have yet to consistently disclose ones pain and therefore can instruct or texture patient outcomes and clinecal conceptions off AD pain.[49] Even so, the nociceptors actions used in the path that leads normally doesn't quite represent discomfort. Even though discomfort is a neurological disorder the qualitative discomfort may take place in the apparent lack of stimulation in the external nociceptor mechanisms. Consequently, throughout the utter lack of discomfort signals, neural circuits normally characterized by pain can exhibit expression. Discomfort complaints can however happen

inside this pain-related areas, witout observed cognitive processing. Are not witout potential drawbacks which depend on neuroscience to experience discomfort in those with real ability to vocally or neurologically express discomfort.

Damage to the Lateral (Sensory) and Medial (Affective) Pain Networks in AD

Its dorsal & vertical trauma loop throughout AD has a welll recognized for its period of injury. When explained earlier in the thread, the destination, frequency, or accuracy of discomfort is modified by both the vertical discomfort system, that modulates emotions of chronic or quick suffering Reports state that throughout AD the horizontal system are less impacted. Alternatively, the marginal discomfort channel facilitates the intense, adaptive response to aversive stiimuli but early in the process of disease the neurodevelopmental adjustments in AD influence the public control system.[49]

Behavioral Display of Pain in AD

When discomfort-related psychological analysis is usually suggested in young adult with auditory or disabilities as part of an overall discomfort analysis, neuropsychological study investigates the function of occipital lobes discomfort technologies, including some that collide with the spinal discomfort structure, which possibly give useful insighht into to the area of psychosocial discomfort analysis in folks with AD. Researches for Ad neuroscience indicate that systems including amygdaala, parietal lobes, gyrus, PAaG, but hippocampus in the occipital lobes trauma system often develop tau creases and neuritiic statues. Across a few environments damage is correlated with impaired interpersonal behaviors For eg, in the striatum, tau clumps are correlated to unusual behavioral movements, and dorsal ventral tegmental area neuriitic tombstones lead to complacency. In fact, AD disease greatly impairs the amygdala, and elderly individuals with severe AD could be at increased riisk for little to responsiveness to discomfort. nA latest fMaRI

research fonud diminished detection well into the hippocampus (ventral segment) between many coagnitively intackt (MmMSE > 25) elderly adolescents in reaction to observational discomfort relative with such a normal younge cohort (median agae = 26).

Consequently, and it might be popular for the hypothalamus to reveal associated withh incresed excitation in persons with AD that have no motor (developmental) discomfort shows comparison to untreated elderly persons. Reasearch examining psychological showcase of discomfort in folks to AD demonstrates that though the skin comments to severe discomfort could boost in peple with severe to reasonable AD, cyclic vomiting-related activities may drop substantially in peple with mental cogenitive decline or AD.

Proposed conceptual framework of pain in people with AD

Developers propose a framework for modeling and evaluating mass reduction, cognitive ability, and cognitive function research in patients with AD based on the peripheral, dorsal, and cortex stress systems and on current facts. Initially, the y-axiis refleacts levels of sevaerity of the disease observed in the total study (no AD, miled , modearate, and quite extreme. That last segment to the left means the predicted liberal skeletal muscle mass reduction. That right image describes the MMmSE ratings as a metric for deterioration seriousness, no deterioration = MMmSE of mield to modearate deamentia = MMmSE = 18, severe deamentia = MMmSE = 10, but very bad deamentia = MMmSE < 2 (mention: several invests MmMSE ratings between 3 to 10). That x axis provides the average trend of AD brain ischaemia, or the cost report indicates an overall elevated task-related cognitive abilities that exists in persons to mield to severe AD including those with APoOE-4 alllele. Namely, owing to the presence of lack of intellectual density in neurons, decreased development in slight and medium AD appears to happen in mind. Yet another proposition is that during persons at risk of AD, including thosae with AD-relaated head trauma, an offsetting redeployment of nerve cells is intended to secure

cerebellar purpose. A further potential explanation is that pd clients have reduced the prefrontal blod circulation end/or unique floow linking to brain activity and metabolites. However to dates no study have studied the stimulation of the hippocampus in sevaere AD, we conclude that offsetting processes malfunction in sevaere AD due to decresed stimulation. That fourthh,sixthh, and seventhh pillars represent the dorsal (effective), rostrale (behavioral), et dorsal (neural) streams of discomfort, collectively. The AD physiological and pathology tests has specifically demonstrated thatthe dorsal (auditory) network function persists stable quite deep in the disorder, whereas the dorsal (affecttive) and rostrale(behavioral) processes are sooner disrupted in the patient's condition. Severe discomfort, or chronice fatigue can normal, enhanced, or reduced relative to therapeutic patients, depends on the severity of AD, effective, physiological, and perceptual data.

Amyloid plaque and neurofibrillary tangle formation in alzheimer's diseases



Alzheimr's diseases is one of the severest neurologic disorders in the region. Therapeutically, it is described by the development of epithelial beta amyloeid with intercellular brilllary neurofii tengles, which contribute to neural malfunction and dying of cells. Normal maintenance of the esential enzyme Aapp (Amyloid al. Precursour Protain) and infection is important to this disease. Within steady levels, a-secretase eventually translocates AaPP to generate saAPP and a carboxyl-terminal fragments C83. That existence of saAPP is associated with ordinary neura[23]l signalling which results in neuronal neural function, working memoary, psychological function, and preservation. AaPP is concurrently inactivated in the infection government to make another intracellularly segment named A all-440/42 by β-secretease & π-secreatase. These neuroprotective segment frequently gathers and contributes as much as 40/42 in polymerization and collagen development with A. Obstructed proteins, devastation of sodium celll function, metabolic chromosomal pressure, damaged fat storage and uneven

fat oxidation and, finally, mortality of neural stem cells, lead in agglomeration. That disease of Alzheimar's often includes the creation of brillant achieve a good clumps. Such clumps were its result of its dephosphorylation of microtubulea-associated protin Taue. GSKe-3 & CDKe5 were the neurotransmitter receptors primarily responsibal by Taue's methylation, since other neurotransmitter receptors including PKCe, PKAe, and Erka2 are known. Taue hyperphosphorylation occurs in depersonalization of Taue from the membrane protain, which leads in microtubuler destabilisation through oligoemerisation of Taue protain inside the molecule. Taue tangales develop and lead to angiogenesis of the neurons as a product of the Taue oligomerization. [23]

Clinical decision in Alzheimer's diseases

That aim for physical therpy for the treatmant Alzheimr's diseases is to make it easier for people to function as appropriately as easier. Enhancing the client's working in daily life involves a method of medical education. Medical philosophy is generally reiterating what people should do, however the dynamic intervention is needed in what a persan will really do may not be considered. A framework, created by humon profession paradigm, was built to direct therapeutic choice-making for persons with Dementia[51][52]. Application of this framework is illustrated by situation execution.

Treament of AD

Dementia syndrome, marked by progressive loss of memary and executive ability, impacts around 15 milllion individuals worldwilde. The rate steadily grows during age 85 from 0.5 percnt each year at age 65 to about 8 a centper annum. That incidence increases around 4.3 percent at aged 65 to 47 per million at age 85 when longevity is common for a lifetime. Abnormalities in the enzyme genome cytokine receptor and extra security 1 and 2 genomes induce previously existing uncommon, mainly hereditary forms of diseases.[52]

Conclusion

Neurological disorders are a societal, scientific, and financial crisis, and are an important field of neurological concern. Pain can be one of the most debilitating symptoms and a way to express emotional misery. motor and sense impairment can specifically cause pain, as is the case for multiple sclerossis in Alzheimer's, from which the motor impairment can impair objective expression. In alzheimr disease, discomfort could be causd by many differant factors like agae-related muscular structural degradation, lethargy or disease progression in the brain aras in pain management, whereas brain injury can reduce experience of perceived discomfort. That current report revealed a primary care recklessness over suffering, when no regard is provided to the disorder 's core signs. Evenso, discomfort is mainly experienced among clinicians with other disorders like parkinsn's, frontotemporal dementia and recurrent, severe neuropathies pending the specific assessment. Even in Alzheimr's diseases, where special care is being paid and specific steps are being made, suffering does not appear to be a major issue but rather deserves full care. In rare instances like Huntingtonn's diseases, discomfort perception can impaired, as well as its sources might be underappreciated and disregarded; Owing to the minimal services generally dedicated to injury, there are no diagnostic tests and specific care plans authorized, so injury control is normally focused on the diagnosable approach of nsaids so antipsychotics lacking thorough analysis of the triggers. Latest work on the role of discomfort in inflammatory disorders demonstrates the ability for psychiatrists to engage effectively in stress management Bringing into consideration its origins and pathways, with extra attenttion to the predilection of diseases triggers, utilizing and reinforcing various measures of perceptual response medical and functional evaluation Assisting pharmaceutical or even un-pharmacological experiments. A query "Will your experience or has he / she become thinking rationally?" despite the universality of the person who has suffered discomfort. 'throughout finalizing the standard treatment alternative, the routine assessment of neurological disorder will be followed by close review and recognition of the relation of crippling effects to the international prevalence of the diseases.

REFERENCES

1.A. E. Harding, "Classification of the hereditary ataxias and paraplegias," *The Lancet*, vol. 321, no. 8334, pp. 1151–1155, 1983.View at: Publisher Site | Google Scholar

2.S. Fujioka, C. Sundal, and Z. K. Wszolek, "Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics," *Orphanet Journal of Rare Diseases*, vol. 18, pp. 8–14, 2013.View at: Publisher Site | Google Scholar

3.A. Sailer and H. Houlden, "Recent advances in the genetics of cerebellar ataxias," *Current Neurology and Neuroscience Reports*, vol. 12, no. 3, pp. 227–236, 2012.View at: Publisher Site | Google Scholar

4.L. Schöls, P. Bauer, T. Schmidt, T. Schulte, and O. Riess, "Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis," *The Lancet Neurology*, vol. 3, no. 5, pp. 291–304, 2004.View at: Publisher Site | Google Scholar

5.J. Sequeiros, S. Martins, and I. Silveira, "Epidemiology and population genetics of degenerative ataxias," in *Handbook of Clinical Neurology*, S. H. Subramony and A. Dürr, Eds., vol. 103 of *Ataxic Disorders*, chapter 14, pp. 227–251, Elsevier, Edinburgh, UK, 3rd edition, 2011.View at: Publisher Site | Google Scholar

6.T. Matsuura, L. P. W. Ranum, V. Volpini et al., "Spinocerebellar ataxia type 10 is rare in populations other than Mexicans," *Neurology*, vol. 58, no. 6, pp. 983–984, 2002.View at: Publisher Site | Google Scholar

7.J. Johansson, L. Forsgren, O. Sandgren, A. Brice, G. Holmgren, and M. Holmberg, "Expanded CAG repeats in Swedish spinocerebellar ataxia type 7 (SCA7) patients: effect of CAG repeat length on the clinical manifestation," *Human Molecular Genetics*, vol. 7, no. 2, pp. 171–176, 1998.View at: Publisher Site | Google Scholar

8.A. Szende and A. Williams, Eds., *Measuring Self-Reported Population Health: An International Perspective Based on EQ-5D*, Euro-Qol Group, Budapest, Hungary, SpringMed Publishing, 2004.

9.M. Rossi, S. Perez-Lloret, L. Doldan et al., "Autosomal dominant cerebellar ataxias: a systematic review of clinical features," *European Journal of Neurology*, vol. 21, no. 4, pp. 607–615, 2014.View at: Publisher Site | Google Scholar

10. N. Whaley and R. Uitti, "Clumsy gait and leg pain," in *Movement Disorders: 100 Instructive Cases*, S. Reich, Ed., pp. 239–244, Taylor & Francis Group, Boca Raton, Fla, USA, 2008.View at: Google Scholar

11. X. Miao, X. Wu, and W. Shi, "Umbilical cord mesenchymal stem cells in neurological disorders: a clinical study," *Indian Journal of Biochemistry and Biophysics*, vol. 52, no. 2, pp. 140–146, 2015.View at: Google Scholar

12. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. *Neuron* 39(6), 889–909.

13. Girault JA, Greengard P (2004) The neurobiology of dopamine signaling. *Arch. Neurol.* 61(5), 641–4.

14. Imai Y, Lu B (2011) Mitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorder. *Curr. Opin. Neurobiol.* 21(6), 935–41.

15. Patten DA, Germain M, Kelly MA, Slack RS (2010) Reactive oxygen species: stuck in the middle of neurodegeneration. *J. Alzheimers Dis.* 20 Suppl 2, S357–67.

16. Springer W, Kahle PJ (2011) Regulation of PINK1-Parkin-mediated mitophagy. *Autophagy* 7(3),266–78.

17. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. *Nat. Med.* 10 Suppl, S2–9.

18. Chen JX, Yan SS (2010) Role of mitochondrial amyloid-beta in Alzheimer's disease. *J. Alzheimers Dis.* 20 Suppl 2, S569–78.

19. Claeysen S, Cochet M, Donneger R, Dumuis A, Bockaert J, Giannoni P (2012) Alzheimer culprits: cellular crossroads and interplay. *Cell. Signal.* 24(9), 1831–40.

20. Marcus JN, Schachter J (2011) Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease. *J. Neurogenet.* 25(4), 127–33.

21. Müller WE, Eckert A, Kurz C, Eckert GP, Leuner K (2010) Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease--therapeutic aspects. *Mol. Neurobiol.* 41(2-3), 159–71.

22. Nizzari M, Thellung S, Corsaro A, Villa V, Pagano A, Porcile C, Russo C, Florio T (2012) Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling. *J Toxicol* 2012, 187297.

23. Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. *J. Biol. Chem.* 283(44), 29615–9.

24. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison. Acta Neurol Scand. 1995;91:98–102. Mesec A, Sega S, Trost M, Pogacnik T. The deterioration of cardiovascular reflexes in Parkinson's disease. Acta Neurol Scand. 1999;100:296–9.

25. Sriranjini SJ, Ganesan M, Datta K, Pal PK, Sathyaprabha TN. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson's disease. Neurol India. 2011;59:659–63.

26. Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord. 2009;24:1747–51.

27. P. Werner, J. Cohen-Mansfield, V. Watson, and S. Pasis, "Pain in participants of adult day care centers: assessment by different raters," *Journal of Pain and Symptom Management*, vol. 15, no. 1, pp. 8–17, 1998.

28. P. Mäntyselkä, S. Hartikainen, K. Louhivuori-Laako, and R. Sulkava, "Effects of dementia on perceived daily pain in home-dwelling elderly people: a population-based study," *Age and Ageing*, vol. 33, no. 5, pp. 496–499, 2004.

29. J. W. Shega, G. W. Hougham, C. B. Stocking, D. Cox-Hayley, and G. A. Sachs, "Pain in community-dwelling persons with dementia: frequency, intensity, and congruence between patient and caregiver report," *Journal of Pain and Symptom Management*, vol. 28, no. 6, pp. 585–592, 2004.

30. S. Zwakhalen, R. Koopmans, P. Geels, M. Berger, and J. Hamers, "The prevalence of pain in nursing home residents with dementia measured using an observational pain scale," *European Journal of Pain*, vol. 13, no. 1, pp. 89–93, 2009.

31. L. Nègre-Pagès, W. Regragui, D. Bouhassira, H. Grandjean, and O. Rascol, "Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey," *Movement Disorders*, vol. 23, no. 10, pp. 1361–1369, 2008.

32. G. Defazio, A. Gigante, P. Mancino, and M. Tinazzi, "The epidemiology of pain in Parkinson's disease," *Journal of Neural Transmission*, vol. 120, no. 4, pp. 583–586, 2013.

33. P. Valkovic, M. Minar, H. Singliarova et al., "Pain in Parkinson's disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life," *PLoS ONE*, vol. 10, no. 8, Article ID e0136541, 2015.

34. M. Tinazzi, S. Recchia, S. Simonetto et al., "Muscular pain in Parkinson's disease and nociceptive processing assessed with CO_2 laser-evoked potentials," *Movement Disorders*, vol. 25, no. 2, pp. 213–220, 2010.

35. L. Ganzini, W. S. Johnston, and W. F. Hoffman, "Correlates of suffering in amyotrophic lateral sclerosis," *Neurology*, vol. 52, no. 7, pp. 1434–1440, 1999.

36. M. P. Jensen, R. T. Abresch, G. T. Carter, and C. M. McDonald, "Chronic pain in persons with neuromuscular disease," *Archives of Physical Medicine and Rehabilitation*, vol. 86, no. 6, pp. 1155–1163, 2005.

37. V. C. J. Wallace, C. M. Ellis, R. Burman, C. Knights, C. E. Shaw, and A. Al-Chalabi, "The evaluation of pain in amyotrophic lateral sclerosis: a case controlled observational study," *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, vol. 15, no. 7-8, pp. 520–527, 2014.

38. F. Hanisch, A. Skudlarek, J. Berndt, and M. E. Kornhuber, "Characteristics of pain in amyotrophic lateral sclerosis," *Brain and Behavior*, vol. 5, no. 3, Article ID e00296, 2015.

39. X. Moisset, C. Cornut-Chauvinc, P. Clavelou, B. Pereira, R. Dallel, and N. Guy, "Is there pain with neuropathic characteristics in patients with amyotrophic lateral sclerosis? A cross-sectional study," *Palliative Medicine*, vol. 30, no. 5, pp. 486–494, 2016.

40. C. E. van t'Hof, S. M. G. Zwakhalen, and J. P. H. Hamers, "Interventions after diagnosing pain in nursing home residents with dementia: the pilot implementation of an observational pain scale (PACSLAC-D)," *Tijdschrift voor Gerontologie en Geriatrie*, vol. 42, no. 2, pp. 67–78, 2011.

41. C. Grimby, J. Fastbom, Y. Forsell, M. Thorslund, C. B. Claesson, and B. Winblad, "Musculoskeletal pain and analgesic therapy in a very old population," *Archives of Gerontology and Geriatrics*, vol. 29, no. 1, pp. 29–43, 1999.

42. S. D. Horn, S. A. Bender, N. Bergstrom et al., "Description of the national pressure ulcer long-term care study," *Journal of the American Geriatrics Society*, vol. 50, no. 11, pp. 1816–1825, 2002.

43. B. S. Black, T. Finucane, A. Baker et al., "Health problems and correlates of pain in nursing home residents with advanced dementia," *Alzheimer Disease and Associated Disorders*, vol. 20, no. 4, pp. 283–290, 2006.

44. J. Kappesser, A. C. D. C. Williams, and K. M. Prkachin, "Testing two accounts of pain underestimation," *Pain*, vol. 124, no. 1-2, pp. 109–116, 2006.

45. M. Kunz, S. Scharmann, U. Hemmeter, K. Schepelmann, and S. Lautenbacher, "The facial expression of pain in patients with dementia," *Pain*, vol. 133, no. 1–3, pp. 221–228, 2007.

46. M. Kunz, V. Mylius, S. Scharmann, K. Schepelman, and S. Lautenbacher, "Influence of dementia on multiple components of pain," *European Journal of Pain*, vol. 13, no. 3, pp. 317–325, 2009.

47. K. Herr, K. Bjoro, and S. Decker, "Tools for assessment of pain in nonverbal older adults with dementia: a state-of-the-science review," *Journal of Pain and Symptom Management*, vol. 31, no. 2, pp. 170–192, 2006.

48. L. J. Cole, M. J. Farrell, E. P. Duff, J. B. Barber, G. F. Egan, and S. J. Gibson, "Pain sensitivity and fMRI pain-related brain activity in Alzheimer's disease," *Brain*, vol. 129, no. 11, pp. 2957–2965, 2006.

49. L. J. Cole, M. Gavrilescu, L. A. Johnston, S. J. Gibson, M. J. Farrell, and G. F. Egan, "The impact of Alzheimer's disease on the functional connectivity between brain regions underlying pain perception," *European Journal of Pain*, vol. 15, no. 6, pp. 568.e1–568.e11, 2011.

50. S. J. Gibson, X. Voukelatos, D. Ames, L. Flicker, and R. D. Helme, "An examination of pain perception and cerebral event-related potentials following carbon dioxide laser stimulation in patients with Alzheimer's disease and age-matched control volunteers," *Pain Research and Management*, vol. 6, no. 3, pp. 126–132, 2001.

51. W. P. Achterberg, M. J. C. Pieper, A. H. van Dalen-Kok et al., "Pain management in patients with dementia," *Clinical Interventions in Aging*, vol. 8, pp. 1471–1482, 2013.

52. E. Tan, N. Jokanovic, M. Koponen, D. Thomas, S. Hilmer, and J. S. Bell, "Prevalence of analgesic use and pain in people with and without dementia or cognitive impairment in aged care facilities: a systematic review and meta-analysis," *Current Clinical Pharmacology*, vol. 10, no. 3, pp. 194–203, 2015.

Plagiarism report



72

ORIGINALITY REPORT

9%	7%	8%	3%
SIMILARITY INDEX	INTERNET SOURCES	PUBLICATIONS	STUDENT PAPERS

PRIMARY SOURCES

1	www.sciencedirect.com Internet Source	3%
2	vbn.aau.dk Internet Source	2%
3	Orjan Skogar, Johan Lökk. "Pain management in patients with Parkinson's disease: challenges and solutions", Journal of Multidisciplinary Healthcare, 2016 Publication	1%
4	free.allmedbooks.com Internet Source	1%
5	journals.sagepub.com Internet Source	1%
6	William Dauer, Serge Przedborski. "Parkinson's Disease", Neuron, 2003 Publication	<1%
7	info-centre.jenage.de Internet Source	<1%
	www.ncbi.nlm.nih.gov	

8	Internet Source	<1%
9	Marina de Tommaso, Miriam Kunz, Massimiliano Valeriani. "Therapeutic approach to pain in neurodegenerative diseases: current evidence and perspectives", Expert Review of Neurotherapeutics, 2016 Publication	<1%
10	Monroe, T. B., J. C. Gore, L. M. Chen, L. C. Mion, and R. L. Cowan. "Pain in People With Alzheimer Disease: Potential Applications for Psychophysical and Neurophysiological Research", Journal of Geriatric Psychiatry and Neurology, 2012. Publication	<1%
11	Submitted to The Hong Kong Polytechnic University Student Paper	<1%
12	K. Mohan Iyer. "Chapter 8 Peripheral Nerve Lesions", Springer Science and Business Media LLC, 2019 Publication	<1%

Date: 25/05/2020